- Company
- Hanmi’s P3T for ’Korean GLP-1 obesity drug’ is approved
- by Lee, Seok-Jun Oct 25, 2023 05:24am
- The development of an ‘GLP-1 obesity treatment optimized for Koreans' is gaining momentum. Hanmi Pharmaceutical announced on the 23rd that the Ministry of Food and Drug Safety approved the Phase III clinical trial for its ‘efpeglenatide,’ a glucagon-like peptide 1 (GLP-1) receptor agonist developed by the company. Epeglenatide is a
- Company
- Celltrion’s Remsima SC was approved in the US
- by Chon, Seung-Hyun Oct 24, 2023 05:22am
- On the 23rd, Celltrion announced that it had received marketing authorization for Zymfentra, which is a subcutaneous formulation of its antibody biosimilar Remsima. Remsima is a Remicade biosimilar. Zymfentra has been approved in Europe under the product name Remsima SC. Celltrion said, “Zymfentra is the world’s only infliximab SC f
- Company
- CMV treatment Livtencity can be prescribed at general hosp
- by Eo, Yun-Ho Oct 24, 2023 05:21am
- The cytomegalovirus treatment ‘Livtencity’ can now be prescribed at general hospitals in Korea. According to industry sources, Takeda Pharmaceuticals Korea’s Livtencity has passed the Drug Committees (DCs) of tertiary hospitals in Korea including Samsung Medical Center, Saint Mary's Hospital, Asan Medical Center, and Sinchon Severance H
- Company
- Next-generation antibiotic Zavicefta can be prescribed
- by Eo, Yun-Ho Oct 23, 2023 05:14am
- The new antibiotic drug Zabicefta is entering the prescription range of general hospitals. According to related industries, Pfizer Pharmaceuticals Korea's Zavicefta is being used in tertiary general hospitals such as SMC, Seoul St. Mary's Hospital, Asan Medical Center in Seoul, and Sinchon Severance Hospital, as well as Gangnam Severance
- Company
- New anemia tablets offer increased options
- by Nho, Byung Chul Oct 23, 2023 05:14am
- Whether the introduction of tablet formulations that offer improved convenience in intake in the KRW 100 billion renal anemia treatment market will shift the market paradigm and offer new options for anemia patients is gaining attention. Until now, erythropoietin stimulating agents were the mainstream treatment for anemia caused by chro
- Company
- Forxiga generics take over 30% of market in 6 mths
- by Kim, Jin-Gu Oct 23, 2023 05:14am
- Generic versions of ‘Forxiga (dapagliflozin)’ have increased their share in the market to 30% in half a year since the original Forxiga’s patent expiry. Since April of last year, 63 companies have been fiercely competing in the market after concurrently releasing their respective generic versions, and Boryung Pharmaceutical, Hanmi P
- Company
- Reimb pricing negotiations for Luxturna start in KOR
- by Eo, Yun-Ho Oct 23, 2023 05:14am
- The one-shot retinal dystrophy treatment ‘Luxturna’ has entered its last stage to reimbrursement in Korea. According to industry sources, Novartis Korea recently entered drug pricing negotiations for its Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) with the National Health Insurance Service. Luxturna
- Company
- The DPP4i+SGLT2i diabetes combination drug market
- by Kim, Jin-Gu Oct 23, 2023 05:14am
- The market for diabetes two-drug combination drugs that combine DPP-4 inhibitors and SGLT-2 inhibitors appears to be growing slowly despite the expansion of combination benefits at the beginning of the year. Since last May, two-ingredient combination drugs have appeared on the market one after another, but the cumulative prescriptions for re
- Company
- LG Chem-BR Pharm signs MOU for HP Vitaran in CHN
- by Lee, Seok-Jun Oct 20, 2023 05:31am
- On the 19th, LG Chem announced it had signed a Memorandum of understanding (MOU) with BR Pharm, a regenerative medicine technology research and manufacturing company, for the development and approval of its PN (polynucleotide) skin booster 'HP Vitaran' in China. BR Pharm's 'Vitaran', which LG Chem introduced to the Korean market in Septe
- Company
- Gilead’s TNBC drug Trodelvy is released in KOR
- by Son, Hyung-Min Oct 20, 2023 05:31am
- Gilead Sciences Korea announced on the 18th that it has launched its metastatic triple-negative breast cancer drug ‘Trodelvy (sacituzumab govitecan)’ in Korea. Until now, Trodelvy has been supplied through the Korea Orphan & Essential Drug Center, but from the 18th, Gilead will supply it domestically, and patients will be able to use
